{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:54:56Z","timestamp":1789170896618,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The objective of this analysis was to estimate the incremental cost\u2013utility ratio (ICUR) of dupilumab as an add-on treatment to best supportive care (BSC), versus BSC alone, in Italy for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). A simulation of outcomes and costs was undertaken using a 1-year decision tree, followed by a lifetime horizon Markov model. Clinical data were derived from a pooled analysis of two studies (SINUS-24 NCT02912468 and SINUS-52 NCT02898454). The Italian National Healthcare Service (NHS) perspective was considered. Model robustness was tested through sensitivity analyses. In the base-case analysis, treatment with dupilumab + BSC resulted in an increase in quality of life-adjusted survival (+1.02 quality-adjusted life years (QALY-gained)), compared to the BSC alone. The resulted ICUR was \u20ac21,817 per QALY-gained and it is below the acceptability threshold commonly used in Italy. Both one-way deterministic and probabilistic sensitivity analyses confirmed the robustness of base-case results. The cost\u2013utility analysis showed that dupilumab, as an add-on treatment to BSC, is a cost-effective therapeutic alternative to BSC in the treatment of patients with severe uncontrolled chronic rhinosinusitis with nasal polyps, confirming that it is economically sustainable.<\/jats:p>","DOI":"10.3390\/jpm12060951","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:25:12Z","timestamp":1654856712000},"page":"951","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost\u2013Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7018","authenticated-orcid":false,"given":"Eugenio","family":"De Corso","sequence":"first","affiliation":[{"name":"Otolaryngology Institute-Department of Head and Neck, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Furneri","sequence":"additional","affiliation":[{"name":"EBMA Consulting, 20077 Melegnano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Salsi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, G. da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Sanofi S.p.a., 20158 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Ronci","sequence":"additional","affiliation":[{"name":"Sanofi S.p.a., 20158 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sala","sequence":"additional","affiliation":[{"name":"Sanofi S.p.a., 20158 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-1113","authenticated-orcid":false,"given":"Rossella","family":"Bitonti","sequence":"additional","affiliation":[{"name":"EBMA Consulting, 20077 Melegnano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-2872","authenticated-orcid":false,"given":"Domenico","family":"Cuda","sequence":"additional","affiliation":[{"name":"Director Department of Otorhinolaryngology, G. da Saliceto Hospital of Piacenza, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: A large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMcp1800215","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"381","author":"Hopkins","year":"2019","journal-title":"N. Engl. J. Med. Mass. Med. Soc."},{"key":"ref_5","first-page":"45","article-title":"Nasal polyps in patients with asthma: Prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J. Asthma. Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.waojou.2021.100592","article-title":"ARIA-ITALIA multidisciplinary consensus on nasal polyposis and biological treatments","volume":"14","author":"Lombardi","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/alr.21588","article-title":"Health Utility Outcomes in Patients Undergoing Medical Management for Chronic Rhinosinusitis\u2014A Prospective Multi-Institutional Study","volume":"5","author":"Luk","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A comparison of the EQ-5D and SF-6D across seven patient groups","volume":"13","author":"Brazier","year":"2004","journal-title":"Health Econ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1939-4551-7-25","article-title":"ICON: Chronic rhinosinusitis","volume":"7","author":"Bachert","year":"2014","journal-title":"World Allergy Organ. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/lary.26723","article-title":"What drives productivity loss in chronic rhinosinusitis? A SNOT-22 subdomain analysis","volume":"128","author":"Chowdhury","year":"2018","journal-title":"Laryngoscope"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/lary.25656","article-title":"Productivity Costs Decrease After Endoscopic Sinus Surgery for Refractory Chronic Rhinosinusitis","volume":"126","author":"Rudmik","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_12","first-page":"343","article-title":"The GALEN rhinosinusitis cohort: Chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_14","first-page":"213","article-title":"Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps","volume":"58","author":"Lourijsen","year":"2020","journal-title":"Rhinology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14639\/0392-100X-N1614","article-title":"Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: A change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology","volume":"42","author":"Bellocchi","year":"2022","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/alr.21377","article-title":"When do the risks of repeated courses of corticosteroids exceed the risks of surgery?","volume":"4","author":"Leung","year":"2014","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_19","first-page":"S22","article-title":"International Consensus Statement on Allergy and Rhinology: Rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1945892420936196","article-title":"Predictors of Disease Control After Endoscopic Sinus Surgery Plus Long-Term Local Corticosteroids in CRSwNP","volume":"35","author":"Settimi","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_21","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/lary.27852","article-title":"Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps","volume":"129","author":"Bhattacharyya","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_23","unstructured":"European Medicines Agency (EMA) (2022, March 07). Dupixent: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent."},{"key":"ref_24","unstructured":"Italian Medicines Agency (AIFA) (2018). Reimbursement Regimen and Price of the Medicinal Product for Human Use \u201cDupixent\u201d."},{"key":"ref_25","unstructured":"(2022, March 01). DETERMINA 8 October 2020. GU General Series n.256 on 16-10-2020, Available online: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2020\/10\/16\/256\/sg\/pdf."},{"key":"ref_26","unstructured":"Italian Medicines Agency (AIFA) (2022, March 01). DETERMINA 24 November 2020 GU General Series n.305 on 09-12-2020, Available online: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2020\/12\/09\/305\/sg\/pdf."},{"key":"ref_27","unstructured":"Italian Medicines Agency (AIFA) (2022). Reimbursement and Price Regimen, Following New Therapeutic Indications, of the Medicinal Product for Human Use \u201cDupixent\u201d."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"AB433","DOI":"10.1016\/j.jaci.2018.12.980","article-title":"A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps","volume":"143","author":"Bachert","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study","volume":"143","author":"Han","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","unstructured":"Italian Medicines Agency (AIFA) (2022, May 01). Guidelines for the Compilation of the Dossier for Pricing and Reimbursement Application of a Medicinal Product Pursuant to the Ministerial Decree 2 August 2019, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf."},{"key":"ref_31","unstructured":"Sanofi (2022, May 02). Data on File. Post-Hoc Analyses of SINUS-52 Trial. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-02-25-17-45-00-1741821."},{"key":"ref_32","unstructured":"Sanofi (2022, May 02). Data on File. Summary of the Persistence of Utility Effect Survey, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02414854."},{"key":"ref_33","unstructured":"Expert Opinion (2022, March 02). Sanofi Data on File. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022."},{"key":"ref_34","unstructured":"Agence technique de l\u2019information sur l\u2019hospitalisation (ATIH) Programme de m\u00e9dicalisation des syst\u00e8mes d\u2019information (PMSI; French hospital discharge database). Taux de R\u00e9intervention* des Patients Op\u00e9r\u00e9s en 2012, Available online: https:\/\/www.scansante.fr\/applications\/taux-de-recours-mco."},{"key":"ref_35","unstructured":"Chevalier, J. (2010). Mesure de L\u2019utilit\u00e9 Attach\u00e9e Aux \u00c9tats de Sant\u00e9: Valorisation de L\u2019index D\u2019utilit\u00e9 EQ-5D et \u00c9volution de L\u2019\u00e9chelle Actuelle en France. [Ph. D. Thesis, University Paris Dauphine]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"Janssen","year":"2012","journal-title":"Value Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/lary.21847","article-title":"Health State Utility Values in Patients Undergoing Endoscopic Sinus Surgery","volume":"121","author":"Soler","year":"2011","journal-title":"Laryngoscope"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"Fokkens","year":"2022","journal-title":"Allergy"},{"key":"ref_39","unstructured":"Organisation for Economic Co-operation and Development (OECD) (2022, March 01). Purchasing power parities (PPP). Available online: https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm#indicator-chart."},{"key":"ref_40","unstructured":"Italian Ministry of Health (2013). Rates of Outpatient Services, Supplement n. 8, Official Gazette n. 23."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7175\/fe.v4i2.773","article-title":"VISITE DVG di studio D. Durata e costo delle visite in medicina generale: Il progetto DYSCO","volume":"4","author":"Garattini","year":"2003","journal-title":"Farmeconomia. Health Econ. Ther. Pathw."},{"key":"ref_42","unstructured":"Italian Ministry of Health (2022, May 02). Progetto Mattoni SSN. Pronto Soccorso e sistema 118, Proposta Metodologica per la Valutazione dei Costi Dell\u2019emergenza, Available online: http:\/\/www.mattoni.salute.gov.it\/mattoni\/documenti\/11_Valutazione_costi_dell_emergenza.pdf."},{"key":"ref_43","unstructured":"Italian Ministry of Health (2013). Rates of Hospital Services, Supplement n. 8, Official Gazette n. 23; Attachment 1."},{"key":"ref_44","unstructured":"EUROSTAT (2022, March 07). Estimated Hourly Labour Costs. Available online: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Hourly_labour_costs."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task force-7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF03320660","article-title":"Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia","volume":"11","author":"Fattore","year":"2009","journal-title":"Pharm. Ital. Res. Artic."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/all.14494","article-title":"Economic considerations on the usage of biologics in the allergy clinic","volume":"76","author":"Azzano","year":"2021","journal-title":"Allergy"},{"key":"ref_48","unstructured":"Jommi, C., Cipriani, F., Fanelli, F., Maria, P., and Pedone, C.W. (2022, March 01). L\u2019impatto Della Cross-Copertura di Dupilumab Sulla Spesa a Carico del Servizio Sanitario Nazionale. Available online: https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/2139\/2044?inline=1."},{"key":"ref_49","first-page":"57","article-title":"Analisi costo-utilit\u00e0 di dupilumab per il trattamento della dermatite atopica grave negli adulti in Italia","volume":"7","author":"Costanzo","year":"2020","journal-title":"Glob. Reg. Health Technol. Assess"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jval.2021.11.195","article-title":"POSA50 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Adolescent and Children Patients in Italy","volume":"25","author":"Pedone","year":"2022","journal-title":"Value Health"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S722","DOI":"10.1016\/j.jval.2020.08.1912","article-title":"PRS32 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Type 2 Severe Asthma in Italy","volume":"23","author":"Pedone","year":"2020","journal-title":"Value Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fphar.2017.00288","article-title":"Pricing and reimbursement of biosimilars in central and Eastern European countries","volume":"8","author":"Kawalec","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_53","first-page":"31","article-title":"Valutazione di costo-efficacia dei nuovi farmaci oncologici immessi sul mercato italiano","volume":"1","author":"Martone","year":"2014","journal-title":"Glob. Reg. Health Technol. Assess"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost\u2013effectiveness of interventions: Alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull. World Health Organ."},{"key":"ref_55","unstructured":"National Institute for Health and Care Excellence (NICE) (2022, March 01). Dupilumab for Treating Moderate to Severe Atopic Dermatitis, 2018. Available online: https:\/\/www.nice.org.uk\/guidance\/ta534."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"AB90","DOI":"10.1016\/j.jaci.2016.12.245","article-title":"Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial","volume":"139","author":"Naclerio","year":"2017","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:27:37Z","timestamp":1760138857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jpm12060951"],"URL":"https:\/\/doi.org\/10.3390\/jpm12060951","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}